PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.520
-0.080
-5.00%
After Hours: 1.550 +0.03 +1.97% 17:55 08/07 EDT
OPEN
1.570
PREV CLOSE
1.600
HIGH
1.580
LOW
1.500
VOLUME
416.26K
TURNOVER
--
52 WEEK HIGH
5.62
52 WEEK LOW
0.7800
MARKET CAP
58.46M
P/E (TTM)
-0.5122
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTE stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

PTE News

More
PolarityTE EPS beats by $0.04, beats on revenue
PolarityTE (NASDAQ:PTE): Q2 GAAP EPS of -$0.33 beats by $0.04. Revenue of $2.27M (+70.7% Y/Y) beats by $1.44M. Press Release
seekingalpha · 2d ago
PolarityTE Reports Second Quarter 2020 Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020. PolarityTE will host a conference call and webcast today, August 6, 2020
Business Wire · 2d ago
PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m. Eastern Time.
Business Wire · 07/29 12:00
NAK, STM among premarket losers
Seeking Alpha · 07/28 12:15
HAS, IBN among premarket losers
Seeking Alpha · 07/27 12:20
Miragen Therapeutics leads healthcare gainers; Mallinckrodt and Vaxart among losers
Seeking Alpha · 07/24 15:00
PolarityTE shares are trading higher after the company reported results from its interim analysis of its trial evaluating SkinTE. 72% of patients treated with SkinTE plus SOC achieved wound closure by 12 weeks vs 32% of patients treated with SOC alone
Benzinga · 07/24 13:20
AMD, SWIR among premarket gainers
Seeking Alpha · 07/24 12:24

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About PTE

PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company's PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.
More

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.